Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Dec 31st Santa Cruz will discontinue a
large number of polyclonal products as
a result of the USDA settlement that was
made public May 19th.

Find CST Equivalent

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

REACTIVITY SENSITIVITY MW (kDa) SOURCE
380 Rabbit

Product Usage Information

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

BRCA2 Antibody detects endogenous levels of total BRCA2 protein. The antibody does not recognize BRCA1.


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to amino acids near the amino terminus of human BRCA2. Antibodies are purified by protein A and peptide affinity chromatography.

The breast cancer susceptibility proteins BRCA1 and BRCA2 are frequently mutated in cases of hereditary breast and ovarian cancers and have roles in multiple processes related to DNA damage, repair, cell cycle progression, transcription, ubiquitination, and apoptosis (1-4). BRCA2 has been shown to be required for localization of Rad51 to sites of double stranded breaks (DSBs) in DNA, and cells lacking BRCA1 and BRCA2 cannot repair DSBs through the Rad51-dependent process of homologous recombination (HR) (5). Numerous DNA damage-induced phosphorylation sites on BRCA1 have been identified, including Ser988, 1189, 1387, 1423, 1457, 1524, and 1542, and kinases activated in a cell cycle-dependent manner, including Aurora A and CDK2, can also phosphorylate BRCA1 at Ser308 and Ser1497, respectively (6-10). Cell cycle-dependent phosphorylation of BRCA2 at Ser3291 by CDKs has been proposed as a mechanism to switch off HR as cells progress beyond S-phase by blocking the carboxy terminal Rad51 binding site (11).


1.  Rahman, N. and Stratton, M.R. (1998) Annu Rev Genet 32, 95-121.

2.  Gayther, S.A. et al. (1999) Am J Hum Genet 65, 1021-9.

3.  Kerr, P. and Ashworth, A. (2001) Curr Biol 11, R668-76.

4.  Scully, R. and Livingston, D.M. (2000) Nature 408, 429-32.

5.  Tutt, A. and Ashworth, A. (2002) Trends Mol Med 8, 571-6.

6.  Okada S and Ouchi T (2003) J Biol Chem 278, 2015–20

7.  Cortez, D. et al. (1999) Science 286, 1162-6.

8.  Xu, B. et al. (2002) Cancer Res 62, 4588-91.

9.  Ouchi M et al. (2004) J Biol Chem 279, 19643–8

10.  Ruffner, H. et al. (1999) Mol Cell Biol 19, 4843-54.

11.  Esashi, F. et al. (2005) Nature 434, 598-604.


Entrez-Gene Id 675
Swiss-Prot Acc. P51587


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

9012
BRCA2 Antibody